Vaccine Fails to Help CMV-Positive Stem-Cell Recipients – Managed Care magazine
FiercePharma |
Vaccine Fails to Help CMV-Positive Stem–Cell Recipients
Managed Care magazine ASP0113 (Astellas Pharma Inc./ Vical Incorporated), an investigational DNA vaccine being developed for cytomegalovirus (CMV)-seropositive hematopoietic stem cell transplant recipients, did not significantly improve overall mortality and CMV end-organ … Vical's Astellas-partnered CMV vaccine falls short again, this time in stem cell transplant recipients CMV Vaccine Falls Short in Phase III Trial |
